Language:

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

The lancet oncology, 2019-08, Vol.20 (8), p.1148-1159 [Peer Reviewed Journal]

Elsevier Ltd ;2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30326-2 ;PMID: 31296491

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Author: Bonvalot, Sylvie, PhD ; Rutkowski, Piotr L, Prof ; Thariat, Juliette, Prof ; Carrère, Sébastien, MD ; Ducassou, Anne, MD ; Sunyach, Marie-Pierre, MD ; Agoston, Peter, MD ; Hong, Angela, MBBS ; Mervoyer, Augustin, MD ; Rastrelli, Marco, MD ; Moreno, Victor, MD ; Li, Rubi K, MD ; Tiangco, Béatrice, MD ; Herraez, Antonio Casado, MD ; Gronchi, Alessandro, MD ; Mangel, László, MD ; Sy-Ortin, Teresa, MD ; Hohenberger, Peter, Prof ; de Baère, Thierry, Prof ; Le Cesne, Axel, MD ; Helfre, Sylvie, MD ; Saada-Bouzid, Esma, MD ; Borkowska, Aneta, MD ; Anghel, Rodica, MD ; Co, Ann, MD ; Gebhart, Michael, Prof ; Kantor, Guy, Prof ; Montero, Angel, MD ; Loong, Herbert H, MD ; Vergés, Ramona, MD ; Lapeire, Lore, MD ; Dema, Sorin, MD ; Kacso, Gabriel, MD ; Austen, Lyn, MD ; Moureau-Zabotto, Laurence, MD ; Servois, Vincent, MD ; Wardelmann, Eva, Prof ; Terrier, Philippe, MD ; Lazar, Alexander J, MD ; Bovée, Judith V M G, Prof ; Le Péchoux, Cécile, MD ; Papai, Zsusanna, Prof
Subjects: Apoptosis ; Cancer therapies ; Hematology, Oncology, and Palliative Medicine ; Hypotension ; Infections ; Injection ; Life span ; Liposarcoma ; Nanoparticles ; Pain ; Patients ; Radiation therapy ; Sarcoma ; Skin ; Surgery ; Therapeutic applications ; Tissues ; Tumors
Is Part Of: The lancet oncology, 2019-08, Vol.20 (8), p.1148-1159
Description: SummaryBackgroundPathological complete response to preoperative treatment in adults with soft-tissue sarcoma can be achieved in only a few patients receiving radiotherapy. This phase 2–3 trial evaluated the safety and efficacy of the hafnium oxide (HfO 2) nanoparticle NBTXR3 activated by radiotherapy versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma. MethodsAct.In.Sarc is a phase 2–3 randomised, multicentre, international trial. Adults (aged ≥18 years) with locally advanced soft-tissue sarcoma of the extremity or trunk wall, of any histological grade, and requiring preoperative radiotherapy were included. Patients had to have a WHO performance status of 0–2 and a life expectancy of at least 6 months. Patients were randomly assigned (1:1) by an interactive web response system to receive either NBTXR3 (volume corresponding to 10% of baseline tumour volume at a fixed concentration of 53·3 g/L) as a single intratumoural administration before preoperative external-beam radiotherapy (50 Gy in 25 fractions) or radiotherapy alone, followed by surgery. Randomisation was stratified by histological subtype (myxoid liposarcoma vs others). This was an open-label study. The primary endpoint was the proportion of patients with a pathological complete response, assessed by a central pathology review board following European Organisation for Research and Treatment of Cancer guidelines in the intention-to-treat population full analysis set. Safety analyses were done in all patients who received at least one puncture and injection of NBTXR3 or at least one dose of radiotherapy. This study is registered with ClinicalTrials.gov, number NCT02379845, and is ongoing for long-term follow-up, but recruitment is complete. FindingsBetween March 3, 2015, and Nov 21, 2017, 180 eligible patients were enrolled and randomly assigned and 179 started treatment: 89 in the NBTXR3 plus radiotherapy group and 90 in the radiotherapy alone group. Two patients in the NBTXR3 group and one patient in the radiotherapy group were excluded from the efficacy analysis because they were subsequently discovered to be ineligible; thus, a total of 176 patients were analysed for the primary endpoint in the intention-to-treat full analysis set (87 in the NBTXR3 group and 89 in the radiotherapy alone group). A pathological complete response was noted in 14 (16%) of 87 patients in the NBTXR3 group and seven (8%) of 89 in the radiotherapy alone group (p=0·044). In both treatment groups, the most common grade 3–4 treatment-emergent adverse event was postoperative wound complication (eight [9%] of 89 patients in the NBTXR3 group and eight [9%] of 90 in the radiotherapy alone group). The most common grade 3–4 adverse events related to NBTXR3 administration were injection site pain (four [4%] of 89) and hypotension (four [4%]) and the most common grade 3–4 radiotherapy-related adverse event was radiation skin injury in both groups (five [6%] of 89 in the NBTXR3 group and four [4%] of 90 in the radiotherapy alone group). The most common treatment-emergent grade 3–4 adverse event related to NBTXR3 was hypotension (six [7%] of 89 patients). Serious adverse events were observed in 35 (39%) of 89 patients in the NBTXR3 group and 27 (30%) of 90 patients in the radiotherapy alone group. No treatment-related deaths occurred. InterpretationThis trial validates the mode of action of this new class of radioenhancer, which potentially opens a large field of clinical applications in soft-tissue sarcoma and possibly other cancers. FundingNanobiotix SA and PharmaEngine, Inc.
Publisher: England: Elsevier Ltd
Language: English
Identifier: ISSN: 1470-2045
EISSN: 1474-5488
DOI: 10.1016/S1470-2045(19)30326-2
PMID: 31296491
Source: AUTh Library subscriptions: ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Elsevier Ltd ;2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30326-2 ;PMID: 31296491

Searching Remote Databases, Please Wait